Zelasudil

CAS No. 2365193-22-0

Zelasudil( —— )

Catalog No. M36300 CAS No. 2365193-22-0

Zelasudil (RXC007) is a Rho-related (ROCK) kinase inhibitor for the study of idiopathic pulmonary fibrosis and inflammation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 188 In Stock
5MG 180 In Stock
10MG 275 In Stock
25MG 468 In Stock
50MG 640 In Stock
100MG 892 In Stock
200MG 1200 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Zelasudil
  • Note
    Research use only, not for human use.
  • Brief Description
    Zelasudil (RXC007) is a Rho-related (ROCK) kinase inhibitor for the study of idiopathic pulmonary fibrosis and inflammation.
  • Description
    Zelasudil is a Rho-associated (ROCK) kinase inhibitor. Zelasudil has a ROCK2 binding affinity.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    ROCK
  • Recptor
    ROCK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2365193-22-0
  • Formula Weight
    437.445
  • Molecular Formula
    C22H21F2N7O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (228.60 mM; Ultrasonic )
  • SMILES
    O=C(NCC(F)F)C=1C=CC(=CC1)C=2N=C(NC3=CC=C4NN=CC4=C3C5CC5)N(N2)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lee E, et al. Selective ROCK2 inhibition for treatment of edema and associated conditions: World Intellectual Property Organization, WO2022169946. 2022-08-11.
molnova catalog
related products
  • Cotosudil

    Cotosudil is a ROCK kinase inhibitor with antihypertensive activity and is used to treat or prevent diseases or conditions caused by cataracts, cardiovascular or neurodegenerative diseases or nerve damage.

  • Cucurbitacin A

    Cucurbitacin I, cytotoxic triterpenoid sterols isolated from plants, elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-Kinase.

  • NSC 409012

    NSC 409012 is an active compound.